Liver disease accounts for two million deaths annually and is responsible for 4% of all
deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related …

Background Non-AIDS-defining cancers (NADCs) are now becoming a rising cause of
morbidity among people living with HIV (PLHIV) in the highly active antiretroviral therapy …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Hepatocellular carcinoma is a leading public health concern in sub-Saharan Africa, and it is
most prevalent in young adults (median 45 years [IQR 35–57]). Overall, outcomes are poor …

Liver-related diseases are associated with the high levels of morbidity and mortality in
people living with HIV. Between 13% and 18% of all-cause mortality in HIV-infected patients …

Background Hepatocellular carcinoma (HCC) among type-2 diabetes (T2D) patients is an
increasing burden to diabetes management. This study aims to develop and select the best …

Background It is uncertain whether people with HIV infection have a higher incidence of
hepatocellular carcinoma (HCC) than the general population. Aims To compare the …

Background People with HIV have higher risk of hepatocellular carcinoma than the general
population, partly because of higher prevalence of coinfection with hepatitis B virus (HBV) or …

Background & Aims Tenofovir is recommended as part of the first-line antiretroviral therapy
(ART) to treat people living with HIV (PLWH) with HBV coinfection. However, the effects of …

The evolutionary history of hepatobiliary cancers is embedded in their genomes. By
analysing their catalogue of somatic mutations and the DNA sequence context in which they …